New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2013
10:11 EDTATML, CLF, HAL, HP, GILD, EFX, XLNX, TFM, PWER, PNM, O, MGM, LUFK, GNC, FET, CY, CRK, CRL, RVBDOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Atmel (ATML) upgraded to Buy from Hold at Needham... Best Buy (BBY) upgraded to Overweight from Equal Weight at Barclays... Charles River Labs (CRL) upgraded to Buy from Hold at Jefferies... Comstock Resources (CRK) upgraded to Outperform from Market Perform at BMO Capital... Cypress Semiconductor (CY) upgraded to Buy from Hold at Needham... Forum Energy (FET) upgraded to Outperform from Market Perform at FBR Capital... GNC Holdings (GNC) upgraded to Buy from Neutral at Goldman... Lufkin (LUFK) upgraded to Outperform from Market Perform at Wells Fargo... MGM Resorts (MGM) upgraded to Outperform from Sector Perform at RBC Capital... Realty Income (O) upgraded to Buy from Neutral at BofA/Merrill... PNM Resources (PNM) upgraded to Buy from Hold at Jefferies... Power-One (PWER) upgraded to Strong Buy from Outperform at Raymond James... The Fresh Market (TFM) upgraded to Buy from Neutral at Goldman... Xilinx (XLNX) upgraded to Buy from Neutral at BofA/Merrill... Equifax (EFX) upgraded to Overweight from Equal Weight at Evercore... Best Buy (BBY) upgraded to Buy from Hold at Stifel Nicolaus... Gilead (GILD) upgraded to Outperform from Neutral at Credit Suisse... Helmerich & Payne (HP) upgraded to Overweight from Equal Weight at Stephens... Halliburton (HAL) upgraded to Overweight from Equal Weight at Stephens... Cliffs Natural (CLF) upgraded to Overweight from Neutral at JPMorgan... Riverbed (RVBD) upgraded to Strong Buy from Buy at Needham.
News For ATML;CRL;CRK;CY;FET;GNC;LUFK;MGM;O;PNM;PWER;TFM;XLNX;EFX;GILD;HP;HAL;CLF;RVBD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
October 13, 2014
08:07 EDTATMLAtmel partners with IHR in automotive electronics
Subscribe for More Information
07:56 EDTGILDGilead Harvoni pricing 'very reasonable,' says RBC Capital
Subscribe for More Information
07:39 EDTGILDPharmaceutical Care Management Association to hold annual meeting
Subscribe for More Information
07:15 EDTHPNational Association of Corporate Directors to hold a conference
Subscribe for More Information
07:12 EDTRVBDRiverbed news already priced into stock, says JMP Securities
Subscribe for More Information
06:49 EDTCLFCliffs Natural downgraded to Neutral from Overweight at JPMorgan
Subscribe for More Information
06:25 EDTMGMMGM Resorts win in Japan could add $11 per share, says Citigroup
Citigroup estimates shares of MGM Resorts could rally $11 should the company win a gaming license in Osaka, Japan. Citi expects the gaming bill in Japan to be passed in November, and notes MGM is a major candidate in Osaka. The firm says the Macau slowdown has the least impact on MGM. It lowered its price target for shares to $31 from $32 and keeps a Buy rating on the name.
October 10, 2014
15:27 EDTCLFCliffs held preliminary talks on iron ore assets with Glencore, WSJ says
Glencore had talks that were described as "very preliminary" with Cliffs Natural Resources about its Australian iron ore assets, according to The Wall Street Journal, citing people familiar with the matter. Shares of Cliffs spiked higher following the first headlines from the report, but are now down about 1% in late afternoon trading. Reference Link
15:16 EDTCLFCliffs Natural held preliminary talks on iron ore assets with Glencore, DJ says
14:08 EDTGILDGilead 12-week regimen of Harvoni to cost $94.5K
Gilead said its newly-approved treatment of hepatitis C genotype 1 infection, Harvoni, will be priced at $94,500 for a full 12 week regiment, according to multiple media outlets, which cite a company spokesperson.
13:55 EDTGILDGilead confirms FDA approval of Harvoni
Subscribe for More Information
13:42 EDTGILDGilead hepatitis C treatment Harvoni approved by FDA
The FDA announced the approval of Harvoni to treat chronic hepatitis C virus genotype 1 infection. Harvoni is the first combination pill approved to treat chronic HCV genotype 1 infection, the agency stated. It is also the first approved regimen that does not require administration with interferon or ribavirin, two FDA-approved drugs also used to treat HCV infection, it added. Harvoni is marketed by Gilead.
13:40 EDTGILDFDA approves Gilead hepatitus C treatment Harvoni
Subscribe for More Information
10:29 EDTATMLMicrochip CEO warning on industry correction sinks semiconductors
Shares of a number of semiconductor makers are falling sharply after one of the companies in the space, Microchip Technology (MCHP), warned that it believes the sector had entered a correction. In a note to investors today, research firm FBR Capital said Microchip's comments "could be worrisome, " and the firm responded by taking a more defensive stance on the space. WHAT'S NEW: Microchip, which develops microcontroller and analog semiconductors, estimated that its second quarter revenue would come in at $546.2M, versus its previous guidance of $560.0M-$575.9M and analysts' consensus estimate of $568M. The company said that it had experienced a number of negative trends during the quarter, including a weaker than usual September, weakness in China, and significant inventory builds at its distributor customers. Microchip President and CEO Steve Sanghi claimed his company often sees the turn of the semiconductor industry ahead of others, noting that it reports sales from distribution on a sell-through basis and built a significant amount of inventory in the distribution channel in the September quarter and that it does business with over 80,000 customers. Sanghi stated, "We believe that another industry correction has begun and that this correction will be seen more broadly across the industry in the near future. ANALYST REACTION: In a note to investors today, FBR Capital analyst Christopher Rolland said that Microchip's statements come in the wake of other negative signs for the sector. In August and September, lead times for the sector fell versus the month before, the analyst stated. Additionally, revenue trends at Taiwanese chip makers weakened in August, Rolland stated. The analyst said that Microchip's statements pushed him over the fence, causing him to take a more defensive stance on the sector. He removed ON Semiconductor (ONNN) from FBR's Top Picks list but kept an Outperform rating on the stock, as he believes that its valuation is "very reasonable." Rolland maintained Market Perform ratings on Atmel (ATML), Texas Instruments (TXN), Fairchild (FCS), AMD (AMD), and Applied Micro Circuits (AMCC). Sterne Agee also attributed weakness in the sector to Microchip's warnings, but the firm recommended buying NXP Semiconductors (NXPI), Avago (AVGO), and Skyworks (SWKS) due to their strong product cycles with EMV and upcoming iPhone-iPad launches from Apple (AAPL). In addition, the firm said it would buy Micron (MU) and SanDisk (SNDK) given tight supply, below normal inventory levels, and tailwinds from China. PRICE ACTION: In early trading, Microchip dropped nearly 14% to $39.29, Intel (INTC) fell almost 6% to $31.67, On Semiconductor slid 10% to $7.53, Atmel tumbled 11.5% to $6.61, Texas Instruments slipped 8% to $42.16, Fairchild slumped 10.6% to $12.95, AMD dropped 6% to $2.77, Applied Micro declined 10% to $6.19, and NXP Semiconductors was 14% lower to $55.27.
10:01 EDTHALOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:38 EDTMGMActive equity options trading on open
Subscribe for More Information
09:06 EDTRVBDF5 Networks checks indicate return to stable growth, says Janney Capital
Subscribe for More Information
08:19 EDTGILDMedivir announces Janssen initiates enrolment in phase II IMPACT study
Subscribe for More Information
07:21 EDTGILDFDA PDUFA Date for Gilead Sciences Sofosbuvir is October 10, 2014
Subscribe for More Information
05:53 EDTHALHalliburton upgraded to Buy from Hold at Societe Generale
Societe Generale upgraded Halliburton to Buy with a $75 price target.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use